Indonesia Pharmaceutical Cold Chain Air Logistics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Indonesia Pharmaceutical Cold Chain Air Logistics Market Trends and Insights

Increasing Outsourcing to GDP-Compliant Logistics Providers

The Indonesia pharmaceutical cold chain air logistics market is supported by pharmaceutical manufacturers that increasingly use specialized third-party logistics providers. These requirements are harder for smaller providers to meet across a dispersed national network. Certified operators can therefore offer a more consistent service to manufacturers with complex temperature-control needs. In March 2026, NX Group integrated PT NX Lemo Indonesia Logistik and PT Nippon Express Indonesia under its One Indonesia approach to provide a single contact point across air and ocean freight operations. This type of integration can improve response times and strengthen the position of providers that combine local execution with broader international networks.

Growth of Direct-to-Patient and E-Pharmacy Fulfillment

The Indonesia pharmaceutical cold chain air logistics market is also shaped by the growth of deliveries to patients rather than only to hospitals and clinics. Insulin, fertility treatments, and selected oncology products need stable temperature conditions during delivery to remote locations. Orders in this channel are smaller and more frequent than institutional shipments, which changes packaging and dispatch requirements. Air freight can be necessary when a remote-island delivery would otherwise take several days by road or sea. B-LOG had more than 3,400 fleet units and 15 storage facilities, showing the scale being developed by domestic cold-chain providers^{[1]B-LOG, “Strengthening Cold Chain Services, B-LOG Ready to Support Indonesia’s National Logistics Needs at GIICOMVEC 2026,” B-LOG, b-log.co.id}. The channel increases demand for service models that can manage frequent deliveries without weakening temperature documentation.

Inter-Island Air Bridges and Regional Micro-Hub Development

The Indonesia pharmaceutical cold chain air logistics market depends on dependable air links between Java and the outer islands. Direct cargo routes can reduce handoffs, which lowers the risk of temperature excursions during complex trips. Ahmad Yani International Airport announced a dedicated Semarang to Makassar cargo service in February 2025^{[2]Ahmad Yani International Airport, “Bandara Jenderal Ahmad Yani Semarang Layani Penerbangan Kargo Rute Semarang–Makassar,” Ahmad Yani International Airport, ahmadyani-airport.id}. The capacity gap makes regional micro-hubs a practical opportunity, but operators need cold storage and reliable procedures rather than route capacity alone.

CEIV-Oriented Airport Handling and Premium Shipment Integrity

Airport handling quality has become an important consideration in the Indonesia pharmaceutical cold chain air logistics market. CEIV Pharma certification provides a recognized framework for managing high-value pharmaceutical cargo under controlled conditions. PT Gapura Angkasa obtained CEIV Pharma certification for cargo at Soekarno-Hatta International Airport in May 2026. The certification improves Jakarta’s capability to handle time-sensitive products that need close control during ground transfers. Secondary hubs still have less certified cold-room infrastructure, so they often require validated passive packaging during airport dwell time. This difference places a premium on providers that can protect shipments across both major gateways and smaller regional nodes.

Archipelagic Infrastructure Gaps and High Logistics Costs

The Indonesia pharmaceutical cold chain air logistics market must serve routes that may combine air, road, smaller aircraft, and boat transport. Each transfer adds handling, packaging, scheduling, and documentation requirements. Deep-frozen shipments need dry ice or active containers, which can make handling costs 4 to 6 times higher than ambient cargo rates. This cost burden is most difficult for lower-value temperature-sensitive products, including some generics and over-the-counter biologics. Providers serving eastern routes need enough volume and route density to spread these costs while maintaining validated handling.

Regulatory, Customs, and Qualified-Personnel Complexity

The Indonesia pharmaceutical cold chain air logistics market is constrained by regulatory procedures and a limited supply of qualified cold-chain personnel. Import approvals and customs classification can delay the release of temperature-sensitive products at international gateways. Delays are especially challenging for biologics with limited stability time outside controlled conditions. CDOB 2025 also increased the need for qualified staff and documented responsibilities at pharmaceutical distribution points. The concentration of certified airport cold rooms in Jakarta makes these issues more visible when cargo moves through secondary hubs. Providers that invest in staff training, documentation, and cold-room capability can reduce these operational pressures, although progress will take time across the national network.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Temperature Range: Chilled Volumes Anchor as Ultra-Low Heats Up

Chilled shipments at 0 to 5 °C held 48.34% of the Indonesia pharmaceutical cold chain air logistics market share in 2025. This position reflects the large role of vaccines, insulin, and biological products that require refrigerated handling rather than frozen storage. The chilled category supports routine distribution to hospitals, clinics, and other healthcare facilities. It also aligns with the broad need for refrigerated capacity across the country’s immunization and biologics supply chains. Frozen shipments at -18 °C to 0 °C form an important secondary category for plasma protein products and selected oncology biologics. Ambient shipments support branded medicines and over-the-counter products that can move within 15 to 25 °C conditions.

Deep-frozen and ultra-low shipments below -20 °C are forecast to grow at an 11.93 % CAGR through 2031. The category serves advanced biologics, as well as cell and gene therapies that require cryogenic handling. These medicines require specialized packaging, close temperature control, and clearly managed handoffs. FedEx stated in 2025 that its Asia-Pacific healthcare capabilities included va-Q-tainer solutions that can reach -60 °C. The Indonesia pharmaceutical cold chain air logistics market size for this category will depend on the availability of suitable airport handling and trained personnel. CEIV Pharma practices remain relevant across all temperature ranges because handling discipline is necessary in each controlled corridor.

By Pharmaceutical Product Type: Biologics Lead as Cell Therapies Emerge

Biological pharmaceuticals accounted for 42.67% of the 2025 Indonesia pharmaceutical cold chain air logistics market size by product type. This group includes biologics, biosimilars, vaccines, and blood-derived medicinal products. Their temperature sensitivity and high value per kilogram support the need for controlled air freight. Vaccines and blood-derived products account for major biologic volumes in the country. Biosimilars also add to refrigerated movement as they are used within hospital treatment programs. Small-molecule pharmaceuticals remain a substantial category, although their temperature requirements differ across branded, generic, and over-the-counter products.

Cell and gene therapies are projected to expand at a 14.07 % CAGR from 2026 to 2031. These therapies are beginning from a near-zero base as hospitals develop pilot programs for CAR-T and gene-editing treatments. Their transport can require conditions from -150 °C to -196 °C using liquid-nitrogen vessels. Air freight is essential for inter-island delivery within the limited stability windows of these products. DHL Group expanded its dedicated airfreight cold-chain network in February 2026 to support end-to-end visibility for cell and gene therapy shipments. The Indonesia pharmaceutical cold chain logistics industry is therefore becoming more dependent on cryogenic expertise as demand shifts toward biologics and advanced therapies.

By Shipment Flow: Domestic Routes Dominate, International Corridors Expand

Domestic shipments held 68.37% share of the Indonesia pharmaceutical cold chain air logistics market share in 2025. Inter-island air transport is central to national coverage for products that cannot tolerate long road or sea journeys. In a country with many islands, domestic air freight provides a function that land transport provides in contiguous markets. The route network connects pharmaceutical production and import gateways with provincial hospitals and regional distribution points. Domestic flows often require several stages of handling when a final destination is outside the main Java corridor. That makes consistent procedures at each transfer point a basic service requirement.

International shipments are forecast to grow at an 8.84% CAGR through 2031. Growth is linked to imports of biologics and specialty injectables that are not yet widely produced in Indonesia. International movements also support the country’s increasing participation in clinical trial supply chains. Many shipments enter through consolidation hubs in Singapore, Kuala Lumpur, or Hong Kong before reaching Jakarta. This adds handling events before arrival and makes coordination between carriers, forwarders, and ground handlers important. The Indonesia pharmaceutical cold chain air logistics market can benefit from stronger international corridors when these parties maintain traceability from origin to delivery.

Geography Analysis

Jakarta is the largest internal hub in the Indonesian pharmaceutical cold chain logistics market, with a 44.28% city share in 2025. Soekarno-Hatta International Airport concentrates on pharmaceutical import clearance, controlled storage, and air-cargo handling. PT Gapura Angkasa received CEIV Pharma certification at the airport in May 2026. This provided a recognized quality framework for high-value and time-sensitive cargo during ground handling^{[3]PT Gapura Angkasa, “Gapura Angkasa Obtains CEIV Pharma Certification for Cargo,” PT Gapura Angkasa, gapura.id}. Jakarta’s certified infrastructure attracts international shipments of biologics and specialty medicines. Its dominance also creates a dependency because alternative hubs have less established controlled infrastructure.

Java’s secondary cities form a dense distribution corridor for the Indonesia pharmaceutical cold chain air logistics market. Surabaya is the most significant secondary hub because Juanda Airport relays cargo toward East Kalimantan, West Papua, and Maluku. Bandung and Yogyakarta serve regional healthcare networks and support distribution within Java. The region has the highest concentration of pharmaceutical distributors, making consistent monitoring and documentation particularly important. Its connections to the national import gateway make Java the primary operational base for most providers.

Makassar provides the strongest geographic growth opportunity with 9.31% CAGR through 2026-2031 in the Indonesia pharmaceutical cold chain air logistics market. The same research identified a need for expansion toward a 28,000 m² terminal standard. Medan is the key access point for northern Sumatra, while Denpasar supports Bali’s hospitals and medical tourism demand. Secondary airports generally lack certified pharmaceutical cold rooms, so operators often use validated passive packaging during airport dwell time. This leaves a clear need for more controlled regional handling as traffic shifts beyond Jakarta.